ClinicalTrials.gg
RecruitingNCT07110818CaNICMUpdated Oct 14, 2026

Non-ischemic Cardiomyopathy Registry, Biobank and Imaging Data Repository

An observational study in Non-ischemic Cardiomyopathy, sponsored by Montreal Heart Institute. Recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Montreal Heart Institute · Observational

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Family-based
Time perspective
Prospective
Enrollment
2,000
Sex
All
01

Study summary

The main goal of CaNICM is to create a central database that includes a biobank and an imaging data repository for patients with non-ischemic cardiomyopathy (NICM), as well as for at-risk family members. This includes people who carry rare genetic variants linked to NICM but do not show symptoms, and first-degree relatives.

The specific goals of this database and biobank are to:

Enhance investigators' ability to predict the risk of heart rhythm disorders in patients with NICM.

Optimize the timing and approach for screening family members who may carry the disease - determining who to test, when, and how.

Find the best ways to treat family members early to prevent or slow the disease.

Future Phase - Phase 2 Goal:

4. Prospectively evaluate how well this risk prediction model works in real-life clinical settings, and compare it to the current approach, which is often based on a single risk factor.

Read the detailed description

PATIENT ENROLLMENT:

Eligible patients will be included from collaborating centres. Patients will be contacted by the local investigator or a research coordinator. Willing individuals will be interviewed by the research coordinator and given information about biobank. The consent form will be reviewed and discussed with the coordinator. The investigators will also be available for any questions that the coordinator is unable to answer. Potential participants will have sufficient time to consider participating in CaNICM. Written informed consent will be obtained from eligible patients or legal guardians. Participants will be able to withdraw their participation at any time.

BASELINE DATA COLLECTION:

Clinical data will be collected from consented participants from the electronic medical report and a questionnaire. Images including CMR and Transthoracic echography (TTE) will be collected. ECG in the XML format will also be transferred. Blood samples will be collected for biobanking

Healthcare information will be coded in compliance with Tri Council Policy Statement criteria: direct identifiers will be removed and replaced with a unique study code (research CaNICM ID that does not use personal information such as the participant's health number, social insurance number or name. The coded data will be transferred into the clinical research database using a web-based electronic case report form (eCRF), using Redcap. The clinical research database will be hosted and managed at the Montreal Heart Institute Research center. The research ID uniquely identifying each subject eCRF within the database will be attributed by the research team but the master list of registry participants with their study identifiers will be kept separately from the clinical research database. This master list will be stored in an encrypted file within the research office of each site investigators under their supervision. Only the site investigators and their local research staff will have access to this list.

Baseline data collection and variables:

Baseline clinical data will be collected from consented participants from questionnaire. This includes demographic information and medical information such as the cardiac history, comorbidities, diagnostic test results, genetic testing results, family history and ethnicity, current and previous treatments. For patients who had had a CMR performed more than 2 years prior, baseline data will also be collected retrospectively at this time if available.

Based to contemporary practice (European society of Cardiology 2023 Cardiomyopathy guidelines8, EHRA/HRS/APHRS/LAHRS consensus on the state of genetic testing26 genetic testing will be recommended for probands and family members of families where the patient has a gene-causing variant.

BIOSPECIMEN COLLECTION:

Consented participants will undergo biosampling at enrollment for the primary purpose of DNA isolation and genetic studies. The preferred method is blood sampling using a standard venipuncture. Blood sampling allows for high quality DNA extraction as well as collection of plasma for potential future circulating biomarkers studies.

The CaNICM biobank will be directed by the Beaulieu-Saucier Pharmacogenomics Center (PGx; pharmacogenomics.ca/), operating under Good Laboratory/Clinical Practices (GLP/GCP) standards.

DNA isolation and long-term storage will be done at PGx, while long-term storage of plasma samples will be done at the MHI research center, in dedicated freezers located in a room with restricted access, under the supervision of Dr Julia Cadrin-Tourigny. All study samples will be stored for 50 years. Samples of subjects that withdraw their participation will be destroyed

IMAGING DATA TRANSFER:

For all consented participants, de-identified transthoracic echocardiography (TTE) and cardiac magnetic resonance (CMR) imaging data will be transferred to the Montreal Heart Institute imaging core-lab for central interpretation and long-term storage. At minimum, the following imaging studies are requested:

  1. First available TTE
  2. First available CMR, preferably with gadolinium injection
  3. TTE closest to time of inclusion in the registry
  4. CMR closest to time of inclusion in the registry
  5. Last available TTE
  6. Last available CMR, preferably with gadolinium injection

Digital Imaging and Communications in Medicine (DICOM) imaging data will be de-identified prior to transfer. De-identification will be performed at each site, by removing the patient's name and replacing the clinical identification number with the research CANICM ID. DICOM data will be stored using the Canadian Imaging network infrastructure (canadianimagingnetwork.org).

ECG data transfer:

For all consented participants, all de-identified ECG data in XML format will be transferred to the central database

Other:

Available relevant reports such as Holter reports and tracing, ICD implantation reports and intra-cardiac tracings will be transferred in the PDF format identified only by the study ID

PATIENT FOLLOW-UP:

Participants with a clinical diagnosis of NICM are expected to undergo yearly clinic visits, as per standard care. Participants without yearly clinic visits will be contacted by phone. Follow-up visits will assess for living status, functional class, medication as well as for arrhythmic, heart failure and thromboembolic events. A complete review of the medical record of the prior year will also be performed, including the transfer of medical notes from other hospitals where the participant has sought care if applicable. Follow-up data will be entered by the local investigator and/or research coordinator into an eCRF managed by the Montreal Heart Institute research center. De-identified documentation of clinical events including ECG, intracardiac tracing, clinical notes, imaging reports, and procedural reports will be uploaded to the database for centralized ad-hoc event adjudication.

De-identified DICOM images of TTE and CMR studies performed clinically during follow-up will be uploaded to the MHI imaging core-lab similarly as for baseline imaging studies.

For participants that will undergo biopsy, LVAD implantation or cardiac transplantation, surgical tissue samples will be collected using the Qiagen PAXgene tissue preservation system or equivalent, allowing for future somatic DNA, RNA and proteomic analyses. The samples will be stored at the MHI research center, under the supervision of Dr Julia Cadrin-Tourigny Upon enrollment, study subjects will be offered the option of providing an email contact information directly to the CaNICM study coordination center. This will allow the coordination center to directly contact participants to 1) provide study updates to participants, 2) obtain optional long-term follow-up data from participants, and 3) offer optional participation to future studies, including patient-reported outcome measures studies. At any time, participants can withdraw such contact information.

For family members, a follow-up every 3 years including an ECG, imaging (either TTE or CMR) and a Holter (PAC, NSVT) will be recommended.

02

Conditions studied

  • Non-ischemic Cardiomyopathy

Keywords

  • genetic
  • echocardiography
  • cardiac magnetic resonance imaging
  • biomarker
  • risk prediction model
03

In context

Lead sponsor

Montreal Heart Institute is the lead sponsor of 101 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with NICM (non-schemic cardiomyopathy) as well as at-risk family members including unaffected carriers of rare genetic variants in genes causing NICM and first degree family members

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. \<50% and/or
  2. LVEF 50-55% with presence of late gadolinium enhancement or LV dilatation and being carrier of a non ischemic cardiomyopathy causing gene (Pathogenic or likely pathogenic variant in a Clingen moderate or definite gene)

Exclusion criteria

Exclusion Criteria:

  • A significant other cause of decreased such as:

    1. Coronary artery stenosis (Significant lesion on proximal Left anterior descending or Left main, or ≥2 main branches with stenosis. Significant lesion is defined as >70% of any artery or >50% for the left main artery) or prior history of type 1 myocardial infarction
    2. Significant congenital heart disease requiring intervention
    3. Primary valvular disease including moderate to severe aortic stenosis and moderate to severe mitral stenosis, primary severe mitral regurgitation (secondary valvular disease such as mitral regurgitation/tricuspid regurgitation are not exclusion criteria)
    4. Other distinct entities: Amyloid heart disease, Chagas, Takotsubo, sarcoidosis, hemochromatosis related cardiomyopathy, related cardiomyopathy are excluded
    5. Substances/therapies induced cardiomyopathy only if they are deemed to be the sole explanation for the cardiomyopathy (at the discretion of the enrolling cardiologist)
    6. Clear history of burned out hypertrophic cardiomyopathy
    7. Already had a transplantation at time of first CMR
    8. Refusal to provide

Additional remarks:

Patients aged > 70 years of age at first contact with a cardiologist regarding the cardiomyopathy will be limited to maximum 10% of the total enrolled patients by center.

Patients with risk factors (for example, chemotherapy, radiotherapy, alcohol…) for cardiomyopathy are not excluded unless they are deemed to completely account for the phenotype per the treating physician.

The inclusion is not restricted to adult patients and is planned to be extended to the pediatric population.

All included patients are recommended to have a CMR performed within 3 years of inclusion.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Family-based
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Time to first sustained ventricular arrhythmia

    Spontaneous sustained VT ICD intervention (shock or antitachycardia pacing) Aborted sudden cardiac arrest (SCA) Sudden cardiac death (SCD)

    Time frame: 5 years

  2. Time to first life-threatening ventricular arrhythmia

    defined as VT with a cycle length ≤ 240 ms (≥250 bpm)

    Time frame: 5 years

  3. Time to (aborted) sudden cardiac death in non-ICD carriers

    Time frame: 5 years

  4. Atrial fibrillation and thromboembolic events:

    Atrial fibrillation Stroke or systemic embolism

    Time frame: 5 years

Secondary outcomes

  1. Number of hospitalization or emergency visit for worsening heart failure

    Time frame: 5 years

  2. Rate of end-Stage HF

    Composite of heart transplant, mechanical cardiac support implantation, or cardiovascular death.

    Time frame: 5 years

  3. Number of clinical HF

    Composite of hospitalization or emergency room visit for HF (admission primarily for HF and worsening HF requiring intensification of HF treatment), new prescription of loop diuretic or LVEF decline to \<40% with change ≥ 10% from baseline (TTE or CMR).

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Apr 2030, 71 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2025
First posted
Aug 8, 2025
StartActual
Apr 2, 2024
Primary completionEst.
Apr 1, 2030
CompletionEst.
Apr 1, 2031
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07110818
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Apr 2, 2024
Primary completion
Apr 1, 2030 (estimated)
Completion
Apr 1, 2031 (estimated)
Last update
Oct 14, 2026

Study contacts

Melissa Lavallée
Contact
melissa.lavallee@icm-mhi.org
1-514-376-3330 ext. 4830
Caroline Girard
Contact
caroline.girard@icm-mhi.org
1-514-376-3330 ext. 4058

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion